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Recently, efforts to increase the toolkit which Escherichia coli cells possess for recombinant protein produc-
tion in industrial applications, has led to steady progress towards making glycosylated therapeutic pro-
teins. Although the desire to make therapeutically relevant complex proteins with elaborate human-
type glycans is amajor goal, the relatively poor efficiency of the N-glycosylation process of foreign proteins
in E. coli remains a hindrance for industry take-up. In this study, a systematic approach was used to
increase glycoprotein production titres of an exemplar protein, AcrA, and the resulting glycosylation effi-
ciency was quantified using a combination of Western blots and pseudo Selective Reaction Monitoring
(pSRM). Western blot and pSRM results demonstrate that codon optimising the oligosaccharyltransferase,
PglB, for E. coli expression, increases efficiency by 77% and 101%, respectively. Furthermore, increasing
expression of glycosyltransferase, WecA, in E. coli improves efficiency by 43% and 27%, respectively. How-
ever, increasing the amount of donor lipid used in the glycosylation process did not impact on the glyco-
sylation efficiency in this system, with this specific protein.
 2012 Elsevier Inc. Open access under CC BY license.1. Introduction the glycosylation efficiency, i.e. the percentage of glycosylated tar-The ambition of using bacteria to make complex post-transla-
tionally modified human protein therapeutics remains a major
challenge for the bioprocessing community. The motivation is to
use production systems that are less costly than mammalian
expression systems with a higher level of final product control,
i.e. little or no heterogeneity, is leading to exciting progress.
Although expression of large functional complex proteins in
Escherichia coli, present problems of their own, steady progress
has been made [1]. The production of smaller therapeutic fragment
proteins, working alone or intended for therapeutic fusion proteins,
such as antibody fragments, has been demonstrated as an attractive
alternative [2–4]. Advantages of small therapeutic proteins include
flexibility in structure which increases binding possibilities and en-
hanced penetration of tissues [2]. A significant advantage is the re-
duced costs of production in E. coli. The ability to perform bacterial
N-glycosylation of target proteins in E. coli has been demonstrated
using the well characterised N-glycosylation pathway from
Campylobacter jejuni [5–7]. Although performed in an exemplar
protein, AcrA, sourced from C. jejuni, the process has been shown
to be functional although very inefficient [6,8,9]. In previous work,Y license. 
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right).get protein compared to total target protein, of AcrA was reported
to be just 13% [8]. It is thought that the occupancy rate of a protein
with a specific sugar structure could be dependent on factors such
as the site of the glycosylation consensus sequence and export
pathways, but there is not a general rule [10–12]. The Pgl pathway
is not native to E. coli and therefore metabolic constraints may also
play a significant role in glycosylation efficiency. For this reason, an
iterative metabolic engineering strategy was developed to identify
bottlenecks and highlight potential targets to improve glycosyla-
tion efficiency [8]. A discovery-driven proteomics workflow, using
chemical tagging was employed with a mixture model on graphs
(MMG) approach [13] to suggest pathways that could be altered.
An increase in expression of isocitrate lyase in the glycoxylate shunt
resulted in an increase in glycosylation efficiency of AcrA by almost
3-fold to 48% [8].
Recently, Schwarz et al. [9] glycosylated AcrA and two human
antibody fragments F8 and CH2, using a system where the native
enzyme undecaprenyl-phosphate alpha-N-acetylglucosaminyl 1-
phosphate transferase (WecA) in E. coli was used to add the initial
sugar N-acetylglucosamine (GlcNAc), the same initial sugar found
in human N-glycoproteins. They reported glycosylation efficiencies
of 40% and 5% for the antibody fragments, respectively. The overall
titres of recombinant protein were very low (personal communica-
tion-Flavio Schwarz) and therefore improvements are required in
overall recombinant protein production as well as glycosylation
efficiency. The research presented here was carried out to address
the glycosylation efficiency issue.
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using systematic genetic changes to the E. coli host cell system. A
codon optimised oligosaccharyltransferase gene (pglB) was tested
and quantified using Western blots and pseudo Selected Reaction
Monitoring (pSRM) (see Pandhal et al. [8]). Western blots give an
actual glycosylation efficiency percentage whereas pSRM confirms
this value by providing fold difference changes in glycoprotein nor-
malised by total protein. The effect of increasing WecA expression
was also tested, as this glycosyltransferase recognises GlcNAc and
attaches the sugar to asparagine residues [14]. Finally, the increase
in expression of BacA was also tested. In this system, glycosylation
involves the transfer of a heptasaccharide from an undecaprenyl-
pyrophosphate donor to the asparagine side chain of proteins. BacA
confers undecaprenyl pyrophosphate phosphatase activity [15],
which potentially results in increased availability of undecaprenyl
phosphate for glycoprotein synthesis. An increase in glycosylation
efficiency from increased BacA presence would indicate this as a
bottleneck in this system. The targets for engineering cells are
shown in Fig. 1.2. Materials and methods
All materials were purchased from Sigma–Aldrich (Dorset, U.K.)
unless otherwise stated.
2.1. DNA cloning, PCR, mutagenesis and vectors
The chloramphenicol resistant vectors pACYCpgl [7] and
pACYCpgl2 [9] were implemented here to perform the N-glycosyla-
tion process. PglB is present on both vectors, but was removed in
pACYCpgl to create pACYCpglDpglB. Briefly, pACYCpglwas digested
with BaeI (NEB, Herfordshire, UK) at 37 C for 1 h. After confirma-
tion by agarose gel electrophoresis, the linear DNA was digested
with exonuclease BAL-31 (NEB) for 5, 10, 20 and 30 min at 30 C.
The reaction was stopped by addition of SureClean reagent (Bioline,
London, UK). Overhangs were filled in using Phusion polymerase
(NEB) following the manufacturer’s instructions. After further
clean-up using SureClean reagent, vectors from all four time pointsFig. 1. A schematic representation of an E. coli cell harbouring N-glycosylation
capability. The systematic cellular engineering targets are shown as black boxes
with white borders. The order of steps involved in the N-glycosylation can be
followed using the black dashed arrows. Briefly, a lipid linked oligosaccharide is
built in the cytoplasm using WecA to add the initial GlcNAc sugar to the
phosphorylated lipid. This is transferred using PglK flippase to the periplasm,
where the oligosaccharyltransferase, PglB, recognises the structure and transfers it
onto the target protein (AcrA) on the appropriate consensus sequence. P = phos-
phate group.were re-ligated using T4 DNA ligase (NEB) with manufacturer’s
instructions for one hour at 37 C. Plasmids were transformed into
NEB5alpha competent cells (NEB) and a colony screen (forward pri-
mer GTGATAAAAATCCTATTCTC, reverse primer ACGCGATGCTTT
GAAATATT) was performed. Briefly, sterile pipette tips were used
to transfer colonies into 5 lL water for subsequent PCR and also
to re-streak colonies on fresh LB agar (with antibiotics). The PCR
program was as follows: 95 C for 5 min, and 30 cycles of 95 C
for 30 s, annealing at 55 C for 30 s and extension at 72 C for times
depending on the expected insert size. A final extension step of
72 C for 10 min was included. Following agarose gel electrophore-
sis, PCR products that visually looked reduced in size were sent for
sequencing at the Core Genome Facility (University of Sheffield).
Plasmids with removed pglB were further tested phenotypically
using Western blots to see if glycosylation was abolished (Western
blot in Supplementary materials).
A codon optimised pglB gene was synthesised by DNA 2.0 (CA,
USA) using the GeneDesigner software algorithm. The codon opti-
mised sequence is given in the Supplementary materials, with
screenshots of how the software is used. The gene was provided
on vector pjexpress401 with kanamycin resistance and named
pjexpress401pglB⁄.
WecA was amplified from E. coli K12 DNA using the primer se-
quences presented in the Supplementary materials. PCR was per-
formed as described previously [8], but with an annealing
temperature of 57 C. The amplified gene was purified using Sure-
Clean reagent and digested with restriction enzymes BamHI and
XmaI for 1 h at 37 C. The same digestion was performed on vector
pjexpress401pglB⁄. The vector backbone was purified using a gel
extraction kit (Zymoresearch, Cambridge) and ligated to wecA
using T4 DNA ligase. The vector was named pjexpress401wecA.
This procedure was repeated using bacA amplified from E. coli
K12 DNA using primers given in the Supplementary materials.
However, BamHI and XbaI digestion was used prior to ligation. This
vector was named pjexpress401bacA. The native (non-codon opti-
mised) pglB gene was also amplified from the original pACYCpgl
vector and inserted into pjexpress401 to make pjexpress401pglB
using a similar procedure described above. This vector was used
to re-introduce pglB activity to cells to test pACYCpglDpglB muta-
tion and serve as a control of pjexpress401pglB⁄.
2.2. Cell growth, induction and harvesting
E. coli CLM24 cells [5] were used as host cells for this study.
Ampicilin, kanamycin and chloramphenicol concentrations of
50 lg/ml were used where appropriate. Overnight cultures were
used to seed 500 ml of LB-broth and grown at 37 C with shaking
at 180 rpm. When the optical density (O.D.) at 600 nm reached
0.5, cells were induced with 0.2% L-arabinose and 20 lM IPTG.
20 O.D. units worth of cells were harvested 3 h post induction via
centrifugation at 10,000g for 15 min at 4 C.
2.3. Protein purification
Proteins from the periplasm were prepped and AcrA purified
using his-tag purification as described previously [8]. The resulting
his-tag purification was prepared for quantitation using pSRM and
Western blotting [8].
2.4. Western blots
Western blots were performed as described previously [8], ex-
cept for alterations described briefly below. His-tag purified pro-
tein samples were quantified using RC/DC assay (BioRad, UK)
and 5 lg of total protein was loaded in each well (in 15 lL) com-
bined with 4 loading buffer (1 M Tris–HCl(pH 6.8), 20% glycerol,
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mercaptoethanol) and loaded onto SDS–PAGE gels. After transfer
to nitrocellulose membrane using an iBlot Dry Blotting System
(Life Technologies, CA, USA), membranes were probed using
0.5 lL anti-C-terminal his-tag antibody (Sigma see manufacturer’s
instructions). Detection was performed using chemiluminescence
with Immobilin horseradish peroxidase (HRP) substrate (Milli-
pore, Watford, UK). Western blots were visualised and quantified
using VisionWorks LS (Cambridge, UK). Glycosylation efficiency
was calculated as a percentage using intensity of glycoprotein over
intensity of total (glycosylated and aglycosylated) protein.
2.5. pseudo Selective Reaction Monitoring (pSRM)
Samples were prepared for MS analysis by in-gel trypsin diges-
tion as described previously [8]. After peptide extraction, the sam-
ples were dried and resuspended in buffer I (3% acetonitrile, 0.1%
formic acid) ready for targeted MS quantitation. Briefly, an HCT
Ultra PTM discovery ESI-Ion Trap MS/MS (Bruker Daltonics, Coven-
try UK) was used to perform high selectivity pSRM measurements
of target peptides. The MS was operated in Ultrascan mode with a
3m/z window. Ion accumulation was set to 180,000 with accumu-
lation maximum of 200 ms. The intact masses and fragmentation
transitions were monitored with 3 microscan averages. Reverse
phase separation of peptides was achieved online using a micro-
flow Ultimate 3000 LC system (Dionex, Surrey, U.K.) with 5% buffer
II (97% acetonitrile, 0.1% formic acids) for 10 min followed by an
increment to 40% buffer II for 30 min. A 90% buffer B for 10 min
was then followed by a final return to 5% buffer B for 10 min.
The pSRM scans were analysed using DataAnalysis v4.0
(BrukerDaltonics, Coventry UK). The mean peak area ratios of the
three technical replicates runs for each sample was compared to
the control for each phenotype and relative values were recorded.
This was repeated for biological replicate samples. Changes in gly-
cosylation efficiency were calculated by normalising glycopeptide
relative changes to total protein changes (calculated from agly-
cosylated peptide intensities) and shown as a percentage.3. Results and discussion
The growth rates of engineered E. coli CLM24 cells were not
compromised significantly compared to the control cells (see Sup-
plementary materials). The Western blot analysis had the advan-
tage of calculating an actual glycosylation efficiency value by
comparing glycosylated to aglycosylated band intensity. Although
pSRM was limited to revealing a fold change in glycosylation effi-
ciency only, variation across biological replicates was lower using
pSRM compared to Western blot analysis (10% compared to 30%
respectively). The average technical variation using pSRM was
19%. Table 1 shows the pSRM peptide targets and elution times.
Example spectra are given in the Supplementary materials.
Codon optimised oligosaccharyltransferase PglB was compared
against standard PglB using pjexpress401 vectors and
pACYCpglDpglB, where the native pglB gene had been deleted. Cells
were induced to express both versions of oligosaccharyltransferase
as well as the target glycoprotein AcrA. In order to confirm theTable 1
pSRM targets. The following peptide m/z values were programmed into the HCT Ultra MR
Peptide Modification* Precursor m
NGFKVPQIGVK N/A 1185.7
LYFIDSVIDANSGTVK N/A 1742.0
AVFDNN*NSTLLPGAFATITSEGFIQK Bac(GalNAc)5Glc 4161.1
ATFENASKDFN*R GlcNAc(GalNAc)5 2779.5
* Bac: bacillosamine, GalNAc: N-acetylgalactosamine, GlcNAc: N-acetylglucosamine, Glcdeletion of the pglB gene from pACYCpgl, E. coli CLM24 cells were
induced to produce AcrA with the vectors pECacrA and
pACYCpglDpglB. Western blot analysis showed the presence of
one band, and therefore indicated that only aglycosylated AcrA
was present (see Supplementary materials). This confirmed the
deletion, as PglB is not present to transfer the glycan onto the pro-
tein and hence no glycoprotein is detected. These cells were further
transformed with either (i) vector pjexpress401pglB or (ii) vector
pjexpress401pglB⁄. The resulting Western blot analysis shows
multiple bands indicative of modified AcrA protein (mono and
di-glycosylated) (see Supplementary materials).
Fig. 2A–C shows Western blot and pSRM quantifications of AcrA
from E. coli CLM24 cells containing pACYCpglDpglB and supple-
mented with (i) pjexpress401pglB and (ii) pjexpress401pglB⁄.
Quantifications of theWestern blot show an overall increase in gly-
cosylation efficiency of 77 ± 27% in cells with codon optimised pglB
compared to non-codon optimised pglB. pSRM results show a
101 ± 26% increase in efficiency when pglB is codon optimised.
These results imply that improved expression levels of pglB in
the glycosylation pathway could be a bottleneck in the production
of glycosylated AcrA in E. coli cells and an increase in glycosylation
efficiency is evident by both Western blot and pSRM.
The BacA enzyme, native to E. coli, harbours undecaprenyl pyro-
phosphate phosphatase activity through conversion of undecapre-
nyl pyrophosphate (UND-PP) to undecaprenyl phosphate (UND-P)
[15]. This product is a key lipid intermediate involved in the syn-
thesis of cell wall polymers such as peptidoglycan. The UND-P lipid
is also required as a donor to add the attached heptasaccharide
sugar (donated from sugar nucleotide donors) to the glycosylation
consensus sequence on AcrA (D/E-Z-N-X-S/T, where X and Z can be
any amino acid except for proline). Therefore, an increase in BacA
would potentially increase the donor availability and increase gly-
cosylation efficiency. Fig. 2D–F shows quantifications of the Wes-
tern blot image and pSRM of E. coli CLM24 cells with pECacrA,
pACYCpgl and either a pjexpress401 control plasmid or pjex-
press401bacA. Quantifications using both methods show no signif-
icant change in glycosylation efficiency. It is therefore presumed
that undecaprenyl phosphate availability is not a glycosylation
limiting component in the E. coli system.
WecA protein is native to E. coli and involved in the initiation of
lipopolysaccharide synthesis [16]. This sugar transferase catalyses
the transfer of GlcNAc-1-phosphate onto undecaprenyl phosphate
(UND-P) to form UND-PP-GlcNAc. This protein can also transfer the
GlcNAc onto the UND-P as the initial sugar of the Campylobacter
heptasaccharide rather than the rare sugar bacillosamine. This
new sugar structure is recognised by PglK and PglB in the glycosyl-
ation process [5,17]. Mass spectral evidence of the different glycan
structure has been reported previously [7], although the abun-
dance difference of the two different types has not. Subsequently,
a pACYCpgl2 vector has been created in which the pgl pathway
was modified by deletion of pglD, pglE, pglC, pglF and pglI [9]. The
new glycan is a hexasaccharide of GlcNAc (GalNAc)6 (glucose is
also not added). In order to improve AcrA glycoprotein expression,
WecA synthesis was induced using the pjexpress401wecA vector
and the amount of glycoprotein with the new hexasaccharide
structure was quantified and compared to control cells. TheM software system.
ass m/z Transition ions Retention time (min)
396.2 416, 641 28.6
871.5 791, 904 36.4
1041.4 1696, 1798 39.9
927.7 1188, 1289 23.6
: glucose.
Fig. 2. (A–C) A comparison of glycosylation efficiency in cells expressing native pglB from C. jejuni (control) and codon optimised PglB (PglB⁄). (A) Western blot image. (B)
Glycosylation efficiency calculated fromWestern blot images in part A. (C) Log10 fold change in glycosylation efficiency calculated by Western blots in part A and pSRM. (D–
F) A comparison of glycosylation efficiency in cells over expressing bacA to control cells. (D) Western blot image. (B) Glycosylation efficiency calculated from Western blot
images in part D. (E) Log10 fold change in glycosylation efficiency calculated by Western blots in part D and pSRM. (G–I) A comparison of glycosylation efficiency in cells over
expressing wecA to control cells (G) Western blot image. (H) Glycosylation efficiency calculated from Western blot images in part G. (C) Log10 fold change in glycosylation
efficiency calculated by Western blots in part G and pSRM. The purified AcrA protein was probed with anti-C-terminal histidine antibody.
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43 ± 11% increase in glycosylation efficiency. pSRM calculations
show a 27 ± 5% in glycosylation efficiency. This increase, although
small, shows that WecA is a potential bottleneck for glycoprotein
production in the E. coli system. Increasing its expression level fur-
ther through IPTG induction, without comprising growth rate and
AcrA production, could improve this further.
The aim of using E. coli cells to economically produce therapeu-
tically relevant, glycosylated human protein therapeutics, requires
generating a strain which harbours the highest efficiency of post-
translationally modified target proteins. Metabolic engineering of
cells to improve the amount of protein which carry the specific gly-
cans is one approach, and progress has been made in this area by
identifying targets using proteomics and metabolic network anal-
ysis. This study involved targeting specific metabolic enzymes
and quantifying glycosylation efficiency using Western blots and
pSRM.
The percentage of glycosylated recombinant AcrA protein, pro-
duced in E. coli, was increased by improving expression levels of
oligosaccharyltransferase, pglB. The expression level was improved
by codon optimisation and translated to a 77%and 101% increase in
glycosylation efficiency (using Western blots and pSRM, respec-
tively). The hypothesis that lipid linked precursor could also be a
bottleneck was tested by increasing expression of bacA, which
has undecaprenyl pyrophosphate phosphatase activity. However,
Western blot analysis and pSRM quantification provided evidence
that the hypothesis was unfounded with AcrA protein. The use of
the E. coli native enzyme WecA to add the same glycan as present
in human proteins, GlcNAc, was improved by increasing its expres-
sion. The modest increase in efficiency however (43% and 27%), im-
plies that E. coli cells would have to be modified in tandem with
other cellular engineering strategies in order to produce an ideal
host for human therapeutic protein production.
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